University of Montana

ScholarWorks at University of Montana
University of Montana Conference on Undergraduate Research (UMCUR)
Apr 22nd, 11:00 AM - 12:00 PM

Investigations of Personalized Medicine in Mesothelioma
Abigail Harmon
University of Montana, Missoula, ah133271@umconnect.umt.edu

Mark Pershouse
University of Montana, Missoula, mark.pershouse@mso.umt.edu

Cooper Parsons
University of Montana, Missoula, cooper.parsons@umconnect.umt.edu

Caitlin Peaslee
University of Montana, Missoula, peasleec@ohsu.edu

Follow this and additional works at: https://scholarworks.umt.edu/umcur

Let us know how access to this document benefits you.
Harmon, Abigail; Pershouse, Mark; Parsons, Cooper; and Peaslee, Caitlin, "Investigations of Personalized
Medicine in Mesothelioma" (2022). University of Montana Conference on Undergraduate Research
(UMCUR). 18.
https://scholarworks.umt.edu/umcur/2022/amposters/18

This Poster is brought to you for free and open access by ScholarWorks at University of Montana. It has been
accepted for inclusion in University of Montana Conference on Undergraduate Research (UMCUR) by an authorized
administrator of ScholarWorks at University of Montana. For more information, please contact
scholarworks@mso.umt.edu.

INVESTIGATION OF
PERSONALIZED
MEDICINE IN
MESOTHELIOMA

AUTHORS

Abby Harmon, Mark Pershouse, Cooper
Parsons, and Caitlin Peaslee

AFFILIATIONS

Department of Biomedical and Pharmaceutical Sciences,
University of Montana

ABSRACT

Malignant mesothelioma is a neoplasm that involves lesions on the pleural linings of the lung or the
peritoneal lining of the abdominal cavity. Current standard of care involves a multi-targeted antifolate
drug Pemetrexid and Cisplatin. This regimen results in regression of tumors in 25% of patients. As the
genetics lesions that cause mesothelioma have been elucidated, our understanding of possible
targets of therapeutics has grown. Rational drug design would dictate that we consider genetic
alterations specific to mesothelioma tumor cells and use those to target our therapy. The most
common genetic alterations in human mesotheliomas are the loss of function of three tumor
suppressor genes, PTEN, NF2, and CDKN2A. In this project, we propose to induce hemizygous genomic
deletions of the PTEN locus by using CRISPR/Cas9 nuclease-generating lentiviral vectors targeting
PTEN in a “normal” mesothelial cell model, LP9/htert. Once established as a model system with various
genomic alterations, the model system will be used to test a small set of front line chemotherapeutic
agents for any increased therapeutic index. Theoretically, genes and proteins down stream of these
genetic lesions will make some cancer cells more susceptible to specific inhibitors. Among the drugs
to be tested are novel PI3 Kinase and mTOR inhibitors.

HYPOTHESIS

Our hypothesis is that
PTEN knockout by
CRISPR/Cas9 editing
will result in an increase
in sensitivity of
suppressed cells to
novel inhibitors directed
at the pathways
affected.

METHODOLOGY

CRISPR/Cas9 containing vectors were purchased from GenScript. (Piscataway, NJ)
These vectors were co-transfected with virus packaging vectors to produce infectious viral particles that were used to
transduce LP9/hTert "normal" mesothelial cells.
Puromycin-resistant clones were selected, sequenced and stored for later analysis.
Appropriate clones will be assayed for mRNA expression of the targeted gene, PTEN.
Appropriate clones will be assayed for the level and size of protein (PTEN).
The ability of PTEN to allow a robust apoptosis in the presence of interventions (UV light, camptothesins) will be assessed.
The sensitivity of knockout clones to novel chemotherapeutic agents will be assessed compared to parental LP9/hTert cells.

HEK293FTcells

RESULTS

We were able to create CRISPR/Cas9 knockouts of LP9 mesothelial cells
targeting PTEN, as well as document retention of the CRISPR/Cas9 vector by
Puromycin resistance in the resultant clones. The alteration of the sequence
at the target exon (exon 3), of PTEN was documented. This alteration
appeared to be hemizygous, as predicted in the literature (homozygous
PTEN knockouts are senescent). Lastly, primers have been designed for qPCR
analysis of PTEN mRNA expression.
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